Aims: The present study evaluates the impact of hypoxia-related carbonic anhydrase IX and XII isoenzyme expression as a basic adaptive mechanism to neutralise intracellular acidosis in classical Hodgkin's lymphoma (cHL). + positive compared to CAIX À negative HRS cells (P < 0.001). Seventy-two months' progressionfree survival (PFS) was significantly lower for the CAIX positive group (0.192) compared with the CAIX negative group (0.771) (P < 0.001), while the overall survival (OS) did not differ (P = 0.097). Conclusion: Hypoxic stress-related adaptation -highlighted by CAIX expression -results in cellular quiescence in HRS cells, potentially contributing to the shortterm failure of the standard chemotherapy in cHL.
Introduction
Classical Hodgkin's lymphoma (cHL) is a malignant lymphatic neoplasia of B cell origin characterised by unique cellular changes, including the generation of highly atypical neoplastic proliferation surrounded by a variable extent of reactive elements. 1 Mononuclear Hodgkin-and multinucleated ReedSternberg cells represent a morphological spectrum of aborted B cell maturation, also referred to as HRS cells. 2 The genomic features and related phenotypical changes of the neoplastic compartment have been largely discovered. 3, 4 Despite the generally favourable outcome cHL is complicated, with therapy resistance or disease progression in 25-30% of the patients. 5 Classical HL is frequently accompanied by variable amounts of focal necrosis and stromal reaction, partially appearing as a consequence of regional perfusion defects, especially in the progressive forms of the disease with nodular sclerosis or lymphocyte depletion (syntitial variant) morphology. 6, 7 Similar to many other malignancies, hypoperfusion and related metabolic disbalance may significantly influence the growth characteristics and the biological responsiveness of neoplastic HRS cells. 8 Hypoxia induces a series of adaptive changes in neoplastic cells, the majority of which fall under the control of some key regulators, such as hypoxia inducible factor 1 (HIF-1). 9 The accumulation of HIF-1a was demonstrated in an O 2 -tension-dependent manner inducing a profound genomic reprogramming with the involvement of several hundred genes in both normal and transformed cells. 10 One of the key issues of tumour cell survival following hypoxia is the ability to neutralise intracellular acidosis due to enhanced glucose utilisation and lactic acid production. The HIF-1a-dependent up-regulation of membrane carbonic anhydrase IX and XII (CAIX and CAXII) is an important way to eliminate protons and normalise cytosolic pH in cancer cells. 11, 12 CAIX and CAXII are prominent members of the carbonic anhydrase enzyme family, catalysing bicarbonate production and thus enabling intracellular proton carboxylation and excretion. 13 Physiological CAIX and CAXII expression is limited to a small set of normal cell types of epithelial origin associated with special pH regulatory function, such as the proxymal tubules of the nephron or the gastrointestinal mucosa.
14 However, HIF-1-dependent carbonic anhydrases were repeatedly demonstrated to be abnormally overexpressed in cancer cells. While conventional renal cell cancer and several epithelial cancer types (gastric and lung adenocarcinomas) showed intrinsic CAIX positivity, many other neoplastic tissues and especially non-epithelial cancers (including glioblastoma) expressed CAIX and/or CAXII in a hypoxia-dependent fashion. [15] [16] [17] Based on several studies, a strong prognostic significance of CAIX in different types of cancer (e.g. breast, head and neck, stomach, liver, pancreas, colorectal carcinomas) was suggested. 18 To date, information about CAIX or CAXII in human lymphatic tissues is surprisingly limited. Speculation on the potential influence of hypoxia on the biology of cHL was previously suggested based on experimental Hodgkin's lymphoma model studies, 8, 19 and increased CAIX activity could be measured more specifically in cHL samples. 20 In agreement with these observations, hypoxia-related dynamic up-regulation of CAIX in cultivated B cell lineages was reported more recently. 21 To date, however, clinical aspects have not been addressed, and currently little is known about the role of adaptive cellular response in the development and outcome of cHL. In the present paper, data are provided demonstrating the highly selective expression of CAIX but not CAXII in the neoplastic compartment of cHL in a significant number of cases, also reflecting regional differences within the same lymphoma tissue. We propose that CAIX-related functional changes indicate a special aspect of the involved neoplastic cells, potentially requiring a different anti-cancer strategy. The cohort consisted of cases with various subtypes, including 51 nodular sclerosis (NS), 20 mixed cellularity (MC), six lymphocyte-rich (LR) and four with lymphocyte depletion (LD) morphology. Additional (follow-up) biopsy material was available in 15 cases of the same cohort. Clinical data were collected and disease outcome was determined for a follow-up period of 72 months after diagnosis. Treatment of the patients followed the international recommendations -standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) combination chemotherapy AE radiotherapy -with intensification and/or autologous stem cell transplantation in case of failure of response or progression. Overall survival (OS) and progression-free survival (PFS) was calculated for each case in months, based on electronic patient records.
Materials and Methods

S A M P L E S E L E C T I O
I M M U N O H I S T O C H E M I S T R Y
Representative lymph node biopsy samples were evaluated for morphological signs of focal tissue necrosis following haematoxylin and eosin (H&E) staining; core needle biopsy samples were not included. Immunohistochemistry was performed on serial sections using the rabbit polyclonal antibody clones NB100-417 (Novus Biologicals, Littleton, CO, USA; final dilution 1 : 2000) for CAIX and PA5-52608 (Thermo-Fisher Scientific, Rockford, IL, USA) for CAXII. CD30 antigen was demonstrated by the antibody clone Ber-H2 (Dako-Agilent, Glostrup, Denmark) and Epstein-Barr (EBV)-related latent membrane protein 1 (LMP-1) by the antibody clone CS1-4 (Dako-Agilent). Specific antibody binding was highlighted using the EnVision Flex horseradish peroxidase/diaminobenzidene (HRP/ DAB) + chromogen detection system (Dako-Agilent) following antigen retrieval at pH 9.0 as usual. Reactive/uninvolved lymph node samples were used as negative controls which never presented with any CAIX or CAXII specific signals. Kidney tissue samples with renal cell cancer involvement were used as positive control staining where normal and neoplastic cells of tubular origin showed strong membrane positivity for CAIX and XII, as expected.
Cell proliferation in individual CAIX + cells was rated following dual imunohistochemistry (IHC) reaction for CAIX and Ki-67 in all cases showing a positive reaction, as follows. The nuclear Ki-67 protein was specifically labelled with the antibody clone Mib1 (Dako-Agilent; dilution 1 : 200) and detected by the EnVision Flex HRP/DAB + (brown colour) procedure. This was followed by a second incubation with the CAIX binding primary antibody (see above) that was detected by the Flex HRP system using violet VIP chromogen (Vector Laboratories, Burlingame, CA, USA) as a substrate. This setting clearly differentiated the Ki67-related brown nuclear staining, and the CAIX-specific violet cell membrane staining within the same cells by light microscopy. Methyl-green solution (Vector Laboratories) was used to counterstain unlabelled cell nuclei for tissue orientation.
CAIX-positive slides were digitalised using the Pannoramic digital slide scanner device (3DHistech, Budapest, Hungary) and were further analysed by the Pannoramic Viewer software on-screen. HRS cells with and without membrane-bound CAIX or CAXII expression were counted based on the cell size and morphology. Slides with more than 10 immunostained HRS cells were defined as unambigously positive. Non-HRS positivity of the microenvironment was separately documented; however, quantification was not enabled. For evaluation of the dual-IHC stained samples, up to 300 HRS cells (depending on their total mass) with or without CAIX positivity were considered from different areas of the same slide. Sections containing fewer than 30 representative CAIX + cells were not considered. Nuclear Ki-67-positivity within the CAIX-positive and -negative HRS cell fraction was determined and the relative frequency of Ki-67 expressing cells for both groups was calculated.
Statistical analysis, including Fisher's exact test and Kaplan-Mayer survival analysis, was performed using the IBM SPSS Statistics version 24 software (IBM Analytics, Armonk, NY, USA).
Results
C A I X A N D C A X I I I M M U N O S T A I N I N G P A T T E R N I N C H L
Serial sections with definitive cHL involvement were evaluated for both CAIX and CAXII immunopositivity. We observed a limited but highly selective positive membrane reaction on individual cells with typical HRS morphology when CAIX-specific antibody was applied ( Figure 1A ). In contrast, CAXII immunostaining resulted in more indefinitely positive areas consisting mainly of stromal and immune cell types, also sometimes including HRS cells. ( Figure 1B ). Although both CAIX and CAXII labelling reflected focal areas of the neoplastic proliferation, only CAIX proved to be selective to highlight clusters of HRS cells within masses of non-labelling atypical cells ( Figure 1C,D) . Conversely, the distinction between neoplastic HRS cells and the reactive infiltrate of the microenvironment seemed to be impossible for most of the CAXII immunostained cases.
Initial lymph node samples from 81 patients (male to female ratio was 40 : 41), with a histological diagnosis of cHL were evaluated for characteristics of CAIX enzyme expression. CAIX immunopositivity presented with a clear membrane reaction in 39 of 81 samples (48.1%) ( Table 1) . CAIX + positive HRS cells were generally located in small dyscohesive clusters, but isolated single cells could also be found frequently. CAIX positivity ranged from scattered isolated HRS cells through several small clusters to large sheets of cells with atypical morphology and almost uniform strong immunopositivity (up to 80.0%). In contrast, cells without HRS morphology were generally not marked in the same way. Small foci of stromal cells with a weak and indefinite staining were only occasionally present surrounding strongly positive HRS cells (2 of 81 samples, 2.5%).
The labelling pattern was different for CAXII, where only 18 of 77 evaluated samples (23.4%) displayed distinct membrane HRS cell positivity. In addition, stromal and immune cell reaction could be demonstrated in 50 of 77 cases (64.9%) associated with the CAXII + neoplastic compartment, but more frequently occurred independently due to activity of fibrosis and chronic inflammatory infiltrate.
C A I X , C A X I I A N D T I S S U E N E C R O S I S I N C H L S U B T Y P E S
As expected, we found a clear morphological relation between the appearance of tissue necrosis in H&E-stained slides and the CAIX-expressing neoplastic compartment (Table 1) . Classical necrotic foci presented with a central amorphous mass surrounded by several layers of CAIX-positive HRS cells demonstrated by immunohistochemistry ( Figure 2 ). This repeatedly indicated a direct relation between sublethal hypoxic damage and CAIX up-regulation in the marginal zone lining necrotic foci. CAIX + was present in the great majority (18 of 21) of the samples in which there was necrosis (85.7%). However, CAIX expression frequently occurred in the absence of clear necrotic morphology. While unambigous signs of necrosis could be identified in only 21 of 81 (25.9%), CAIX positivity appeared in 39 of 81 (48.1%) of the samples. CAIX positivity was associated with necrosis in only 18 of 39 samples (46.2%) (P < 0.0001) ( Table 1) .
CAIX expression and necrosis were both found to be strongly dependent on the histological subtype of Hodgkin's lymphoma ( Differences between histological subentities were not striking when CAXII expression was tested, except for the strong correlation of CAXII with the LD subgroup (4 of 4, 100%) ( Table 2) .
In order to evaluate the general functional status of CAIX-expressing HRS cells, we applied the Ki67 cell proliferation marker in a double IHC setting. HRS cells were identified on digital slides based on their morphology following methyl-green counterstaining. Cells with clear membrane IHC staining in violet (VIP) were declared as CAIX + , while brown nuclear staining (DAB) referred to Ki67 positivity (Figure 3) . Following the double IHC evaluation in 26 evaluable (Figure 4 ).
C A I X A N D C A X I I S T A T U S I N R E B I O P S Y S A M P L E S
Fifteen of the 81 cases included in our evaluation had accessible rebiopsy samples taken due to therapy failure or recurrence. Thirteen of 15 cases belonged to the CAIX-expressing cHLs (86.6%). CAIX immunostaining in these samples presented a particular dynamic, and was slightly different from the initial status. Five rebiopsy samples (33.3%) changed to negative during the course of the treatment, while the remainder of the CAIX + cases also showed a reduced frequency of CAIX-positive cells in the follow-up samples. Conversely, none of the negative samples converted to positive, and a significant increase in CAIX expression was also never detected in the follow-up series.
CAXII staining revealed similar results comparing primary and follow-up lymph node biopsies. HRS cell positivity remained unchanged in 10 of 15 rebiopsy Table 2 . Occurrence of necrosis, CAIX+ and CAXII+ HRScells according to histological subtypes in cHL. CAIXexpression was most frequently observed in LD and NS subtypes. All samples of the LD group featured both CAIX+ and CAXII+ HRS-cells (4/4, 100%), this difference was statistically significant compared to any of the other histological subgroups (*P < 0.001, independent-samples t-test) samples (66.6%), but became negative following initial CAXII positivity in 5 of 15 samples (33.3%).
C L I N I C A L I M P A C T O F C A I X A N D C A X I I E X P R E S S I O N I N C H L
Clinical data for the 72 months total time-period were collected and evaluated for the influence of necrosis as well as CAIX and CAXII immunopositivity observed in the primary biopsy sample on general survival for all available cases. The longest survival measured was 138 months from the initial diagnosis. The OS rate was 0.823 and the PFS was 0.504 for the total study population (n = 81), both results reflecting the current clinical standards.
According to the Kaplan-Meier curves and MantelCox statistical analysis, the presence or absence of necrosis in cHL did not influence the overall survival (0.812 versus 0.833, P = 0.469), and despite a mild difference in the PFS, cases featuring tissue necrosis did not perform statistically worse compared to the non-necrotic cases (0.19 versus 0.579, P = 0.146, not significant) ( Figure 5A,B) . The centralised Wilcoxon's (Breslow) test considering the outcome and the duration of the follow-up revealed scores of 0.724 and 0.464, respectively.
Interestingly, a more striking difference was found in relation to CAIX expression ( Figure 5C,D) . While the OS differed only minimally between the CAIXnegative and CAIX-positive groups (0.934 versus 0.699, P = 0.097, statistically not significant), PFS proved to be highly different depending on the CAIX status. Our comparison reflected a highly statistically significant longer cumulative PFS in the CAIX À (0.771) compared to the CAIX + cases (0.19) (P < 0.001) ( Figure 5C,D) . The Breslow scores were 2.032 for OS and 12.162 for PFS. In contrast, OS and PFS did not differ significantly between the CAXII-negative and -positive lymphomas (P = 0.301 and P = 0.524, respectively) in the 77 cases evaluated (Breslow scores were 1.977 and 0.649, respectively) ( Figure 5E,F) .
The positive predictive value (PPV) for an initial treatment failure proved to be 0.76 in the case of CAIX positivity, while the negative predictive value (NPV) was 0.66 for lack of progression in the absence of CAIX expression determined in the initial biopsy sample (P < 0.003). As expected, PPV and NPV for the CAXII was generally weak (statistically not different, no predictive value).
Discussion
The dynamic overexpression of carbonic anhydrases in selected cancers seems to be an important adaptive feature due to hypoperfusion-related tissue hypoxia. The specific role of cell membrane-bound CAIX and CAXII to neutralise intracellular acidosis in neoplastic cells was established in in-vitro and in-vivo models, including knock-down animal model experiments. 22 CAIX has been investigated histologically in a series of cancers, and was found to be associated with aggressive phenotype and/or unfavourable prognosis. 18, 23 Considerably less information is available for CAXII expression at the histological level.
The potential role of hypoxia in the evolution and progression of cHL was not included in the focus of extended clinical or molecular investigations. Hypoxia-related pathways were not reported to be generally activated in HRS cells by gene expression studies 4 or epigenetic profiling. 24, 25 We have demonstrated that, further to hypoxic necrosis, an even more significant fraction of classical Hodgkin's lymphoma is characterised by focal expression of CAIX and CAXII. CAIX IHC showed a strong membrane reaction that proved to be virtually selective for HRS cells with only minimal and indefinite IHC staining in bystander cells, usually in close proximity to the strong HRS cell reaction. Activated large mononuclear tumour cells occasionally seen as CAIXpositive were interpreted as 'precursor HRS cells' sharing the pathobiology of the classical cell type. In contrast, CAXII IHC labelled a series of additional cell types further to the neoplastic compartment. In our interpretation, the CAXII labelling pattern was consistent with the topography of hypoxic stress generally affecting the complex tissue composition of cHL, including inflammatory and regenerative components. Thus, CAXII labelling did not appear to selectively reflect functional changes at the individual cancer cell level, and seemed to be of limited utility to present and interpret the extent of hypoxic adaptation in histological conditions.
In contrast to CAXII, the association between CAIX expression and spontaneous necrosis could be clearly established by histology in untreated primary cHL biopsies. HRS cells with CAIX positivity apparently formed a well-defined compartment surrounding morphologically recognisable necrotic foci. Moreover, CAIX expressing HRS cells could be observed in the great majority (85.7%) of the samples presenting with necrosis by conventional H&E staining, indicating a close relationship between hypoxic damage and CAIX expression. Conversely, more than half the samples with a CAIX positive compartment did not present with morphological signs of necrosis. According to this observation, focal adaptive changes induced by non-lethal hypoxic stress may result in the selective up-regulation of CAIX in HRS cells, and adaptive CAIX expression generally occurs prior to massive cell demage in HRS cells. On the contrary, expression of isoenzyme CAXII -supposed to be regulated by the hypoxia pathway in a similar way -could be demonstrated in neoplastic HRS cells in the minority (23.4%) of the evaluated cases, together with the labelling of further non-neoplastic cell types (fibroblasts, histiocytes and other immune cells) associated with tissue repair.
Despite the limited number of cases of different histological subgroups in our cohort, we found basic differences regarding hypoxia-related features. The frequent occurrence of necrosis and even more frequent CAIX expression in LD and in NS indicate general adaptive and regressive capabilities in these subtypes (in 100% and 56.9% of the cases, respectively). Interestingly, all four cases of lymphocytedepleted cHL presented with areas of necrosis and strong membrane CAIX expression as well as CAXII in up to 80% of the HRS cells in each sample. The LD form presented in the form of a sarcoma-like solid tumour with the most unfavourable behaviour among cHL subtypes. Indeed, three of the four patients with LD cHL and CAIX/CAXII expression died of disease progression within 14 months of diagnosis. In contrast, the general lack of necrosis and low frequency CA expression in LR and MC subtypes of cHL suggest that hypoperfusion-and hypoxiarelated reprogramming is less relevant in the course of these histological forms. Importantly, cancer cells suffering from hypoxia and acidosis tend to aquire regressive features also shared by cancer stem cells. 7, 26, 27 Functional analysis of the tumour cell compartment could be conducted in the present study using a CAIX/Ki-67 double IHC approach. The Ki-67 nuclear protein is a key factor of cell cycle progression, 28, 29 which can be demonstrated with high affinity by the antibody clone Mib-1. 30 The Ki-67 labelling index is widely used to estimate proliferative activity, and as such it is an established prognostic factor in different malignant conditions. [31] [32] [33] including lymphoid neoplasias. 34 Earlier data reported generally high cell proliferation activity in HRS cells with more than 90% cell cycle activity 35 and Ki-67 indices between 57 and 80%. 36, 37 Detailed analysis by Tzankov et al. 35 suggested profound cell cycle regulatory defects behind these high overall ratios. CAIX/Ki67 double immunohistochemistry enabled us to differentiate and demonstrate adaptation-related cell cycle activity in HRS cells for the first time. Unfortunately, a dual IHC setting for CAXII/Ki67 failed due to the high number of CAXII + bystander cells and unsatisfactory identification of the cell composition required for the analysis. The cell proliferation of CAIX-expressing neoplastic cells proved to be strongly repressed (mean 29.72 AE 13.07) compared to the CAIX-negative compartment (mean 69.38 AE 10.79) of the same biopsy sample. Despite the generally high proliferation rate, CAIX positivity was associated with suppressed cell cycle activity in all evaluated samples, irrespective of the histological subtype. Cellular quiescence in the positive HRS cell compartment is in good agreement with the limited actual energy supply of the immediate tissue environment. This observation further supports the beneficial effect of CAIX expression in hypoxia-related adaptation.
Tissue perfusion is generally more likely to be challenged in aggressive forms of cHL. Functional changes due to hypoxic adaptation therefore may have a major clinical impact on the progression and therapeutic response in cHL. As a first attempt, we evaluated the clinical course related to tissue necrosis and adaptation-driven CAIX and CAXII up-regulation in 81 cHL cases. While necrosis had only little effect (P = 0.146) and CAXII did not show any influence (P = 0.524) on therapy response (PFS), cases with CAIX expression had a highly distinct (P < 0.001) unfavourable response to the frontline standard therapy. This effect still remained minimally visible when the overall survival rates were compared (P = 0.097). Thus, CAIX expression in cHL could be associated with the failure of the initial treatment according to standard therapy (ABVD), even in a univariate setting. Both the PPV and the NPV of CAIX expression indicated the strongly elevated likelihood of failure/progression after initial chemotherapy (76.2% and 65.9%, respectively).
Based on these first observations, hypoxia-related adaptive mechanisms seem to have an important role in the complex biology of cHL. In particular, CAIX was found promising to highlight hypoxic cellular damage selectively in the neoplastic compartment. CAIX immunohistochemistry of the primary biopsy specimen may help to predict the initial therapy response and to select high-risk patients at the diagnosis of classical Hodgkin's lymphoma.
